Pharmacological reports : PR最新文献

Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine. 揭示协调荷马碱神经保护潜能的介质的机理相互作用。

Pharmacological reports : PR Pub Date : 2024-05-17 DOI: 10.1007/s43440-024-00602-8

Pankaj Kadyan, Lovedeep Singh

引用次数: 0

Tolerability of N-chlorotaurine in comparison with routinely used antiseptics: an in vitro study on chondrocytes. N-氯牛磺酸与常规防腐剂的耐受性比较：对软骨细胞的体外研究。

Pharmacological reports : PR Pub Date : 2024-05-17 DOI: 10.1007/s43440-024-00601-9

Magdalena Pilz, Kevin Staats, O. Assadian, Reinhard Windhager, J. Holinka

引用次数: 0

Essential phospholipids impact cytokine secretion and alter lipid-metabolizing enzymes in human hepatocyte cell lines. 必需磷脂影响细胞因子的分泌，并改变人肝细胞系中的脂质代谢酶。

Pharmacological reports : PR Pub Date : 2024-04-26 DOI: 10.1007/s43440-024-00595-4

Dominik Wupperfeld, Gert Fricker, Béatrice Bois De Fer, Branko Popovic

引用次数: 0

Role of the β2-adrenergic receptor in podocyte injury and recovery. β2肾上腺素能受体在荚膜细胞损伤和恢复中的作用

Pharmacological reports : PR Pub Date : 2024-04-26 DOI: 10.1007/s43440-024-00594-5

Ehtesham Arif, Ashish Kumar Solanki, Bushra Rahman, Bethany Wolf, Rick G. Schnellmann, D. Nihalani, J. Lipschutz

引用次数: 0

Role of the RAAS in mediating the pathophysiology of COVID-19. RAAS 在介导 COVID-19 病理生理学中的作用。

Pharmacological reports : PR Pub Date : 2024-04-23 DOI: 10.1007/s43440-024-00596-3

J. Jasiczek, Adrian Doroszko, Tymoteusz Trocha, M. Trocha

引用次数: 0

The impact of excessive maternal weight on the risk of neuropsychiatric disorders in offspring-a narrative review of clinical studies. 母亲体重过重对后代患神经精神疾病风险的影响--临床研究综述。

Pharmacological reports : PR Pub Date : 2024-04-22 DOI: 10.1007/s43440-024-00598-1

Magdalena Kacperska, J. Mizera, Maciej Pilecki, L. Pomierny-Chamioło

引用次数: 0

Introduction to the Special Section on "Energy metabolism in the physiology and pathology of the central nervous system". “中枢神经系统生理和病理中的能量代谢”专题导论。

IF 4.4

Pharmacological reports : PR Pub Date : 2022-10-01 DOI: 10.1007/s43440-022-00421-9

Katarzyna Głombik, Katarzyna Kuter-Nowak

引用次数: 0

Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells. sirtuin抑制剂cambinol和紫杉醇在MCF7 luminal和MDA-MB-231三阴性乳腺癌细胞中的加性药理作用

IF 4.4

Pharmacological reports : PR Pub Date : 2022-10-01 Epub Date: 2022-07-28 DOI: 10.1007/s43440-022-00393-w

Anna Wawruszak, Estera Okon, Ilona Telejko, Arkadiusz Czerwonka, Jarogniew Luszczki

{"title":"Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.","authors":"Anna Wawruszak, Estera Okon, Ilona Telejko, Arkadiusz Czerwonka, Jarogniew Luszczki","doi":"10.1007/s43440-022-00393-w","DOIUrl":"https://doi.org/10.1007/s43440-022-00393-w","url":null,"abstract":"Background: Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in women worldwide. Sirtuin inhibitors (SIRTi), belonging to the histone deacetylase inhibitors group (HDIs), are potent epigenetic drugs that have been investigated for therapeutic use in different clinical disorders, including hematological malignancies and solid tumors.Methods: The influence of cambinol (CAM; SIRTi) used individually or in combination with standard chemotherapeutic paclitaxel (PAX) on viability (MTT assay), proliferation (BrdU assay), induction of apoptosis and cell cycle arrest (FACS analysis) was determined in MCF7 luminal and MDA-MB-231 triple-negative breast cancer (TNBC) cells. The types of pharmacological drug-drug interaction between CAM and PAX were determined by an exact and rigorous pharmacodynamic method-an isobolography, to determine the presence of synergism, addition or antagonism between analyzed drugs using a variety of fixed-dose ratios.Results: The combination of CAM and PAX at a fixed ratio of 1:1 exerted additive interaction in the viability of MCF7 and MDA-MB-231 BC cells. Both active agents used separately reduced viability and proliferation of BC cells as well as induced apoptosis and cell cycle arrest. These effects were much more evident in MCF7 than in MDA-MB-231 BC cells. Additionally, CAM combined with PAX increased anti-cancer activity compared to PAX used alone.Conclusion: CAM might be considered a potential therapeutic agent individually or in combined therapy with PAX against luminal or TNBC.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"1011-1024"},"PeriodicalIF":4.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40569781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. 慢性氟西汀治疗对青春期啮齿动物焦虑和抑郁样行为的影响——系统回顾和荟萃分析。

Pharmacological reports : PR Pub Date : 2022-10-01 Epub Date: 2022-09-24 DOI: 10.1007/s43440-022-00420-w

Joanna Kryst, Iwona Majcher-Maślanka, Agnieszka Chocyk

{"title":"Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis.","authors":"Joanna Kryst, Iwona Majcher-Maślanka, Agnieszka Chocyk","doi":"10.1007/s43440-022-00420-w","DOIUrl":"10.1007/s43440-022-00420-w","url":null,"abstract":"Background: Drugs prescribed for psychiatric disorders in adolescence should be studied very extensively since they can affect developing and thus highly plastic brain differently than they affect the adult brain. Therefore, we aimed to summarize animal studies reporting the behavioral consequences of chronic exposure to the most widely prescribed antidepressant drug among adolescents i.e., fluoxetine.Methods: Electronic databases (Medline via Pubmed, Web of Science Core Collection, ScienceDirect) were systematically searched until April 12, 2022, for published, peer-reviewed, controlled trials concerning the effects of chronic fluoxetine administration vs. vehicle on anxiety and depression measures in naïve and stress-exposed adolescent rodents. All of the relevant studies were selected and critically appraised, and a meta-analysis of eligible studies was performed.Results: A total of 18 studies were included in the meta-analysis. In naïve animals, chronic adolescent fluoxetine administration showed dose-related anxiogenic-like effects, measured as a reduction in time spent in the open arms of the elevated plus maze. No significant effects of chronic adolescent fluoxetine on depression-like behavior were reported in naïve animals, while in stress-exposed rodents chronic adolescent fluoxetine significantly decreased immobility time in the forced swim test compared to vehicle.Conclusions: These results suggest that although chronic fluoxetine treatment proves positive effects in animal models of depression, it may simultaneously increase anxiety in adolescent animals in a dose-related manner. Although the clinical implications of the data should be interpreted with extreme caution, adolescent patients under fluoxetine treatment should be closely monitored.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"920-946"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33480342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroendocrine microRNAs linked to energy homeostasis: future therapeutic potential. 与能量稳态相关的神经内分泌微rna:未来的治疗潜力。

IF 4.4

Pharmacological reports : PR Pub Date : 2022-10-01 Epub Date: 2022-09-09 DOI: 10.1007/s43440-022-00409-5

Kimberly W Y Mak, Aws F Mustafa, Denise D Belsham

{"title":"Neuroendocrine microRNAs linked to energy homeostasis: future therapeutic potential.","authors":"Kimberly W Y Mak, Aws F Mustafa, Denise D Belsham","doi":"10.1007/s43440-022-00409-5","DOIUrl":"https://doi.org/10.1007/s43440-022-00409-5","url":null,"abstract":"The brain orchestrates whole-body metabolism through an intricate system involving interneuronal crosstalk and communication. Specifically, a key player in this complex circuitry is the hypothalamus that controls feeding behaviour, energy expenditure, body weight and metabolism, whereby hypothalamic neurons sense and respond to circulating hormones, nutrients, and chemicals. Dysregulation of these neurons contributes to the development of metabolic disorders, such as obesity and type 2 diabetes. The involvement of hypothalamic microRNAs, post-transcriptional regulators of gene expression, in the central regulation of energy homeostasis has become increasingly apparent, although not completely delineated. This review summarizes current evidence demonstrating the regulation of feeding-related neuropeptides by brain-derived microRNAs as well as the regulation of specific miRNAs by nutrients and other peripheral signals. Moreover, the involvement of microRNAs in the central nervous system control of insulin, leptin, and estrogen signal transduction is examined. Finally, the therapeutic and diagnostic potential of microRNAs for metabolic disorders will be discussed and the regulation of brain-derived microRNAs by nutrients and other peripheral signals is considered. Demonstrating a critical role of microRNAs in hypothalamic regulation of energy homeostasis is an innovative route to uncover novel biomarkers and therapeutic candidates for metabolic disorders.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"774-789"},"PeriodicalIF":4.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33455984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1